Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity

For patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA), structured tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to treatment continuation for maintaining disease control over 24 weeks, according to a study